ST Corporation: HW211026 ointment enters phase II clinical trial research.

ST Evergreen announcement, its wholly-owned subsidiary Hubei Biomedical Industry Technology Research Institute Co., Ltd. recently announced the registration information of the II phase clinical trial of HW211026 ointment on the Drug Clinical Trial Registration and Information Disclosure Platform of the National Medical Products Administration. HW211026 ointment obtained approval from the National Medical Products Administration in October 2024 with an indication for the treatment of actinic keratosis.